RxDoctor Payments Data

Caitlin Massey, APRN

Acute Care · Tulsa, OKNPI 1528600350

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Atricure, Inc. at 47.2% of the total. Reporting peaked in 2024 at $3,720 and has fallen 81.3% since, to $697 in 2025.

$4,556in general payments, 2019–2025

Across 44 payments — averaging $103.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$2K
  • Biosense Webster, Inc.$1K
  • Medical Device Business Services, Inc.$861
  • Medtronic$167
  • Abiomed$119
  • Cardiva Medical, Inc.$60
  • plus $68 from 3 others

What the payments were for

  • Travel & lodging$2,32851%
  • Food & beverage$2,19148%
  • Education$361%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,556 in reported general payments places this provider in the 85th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,836
Medicare patients
258
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$172,814
MultaqDronedarone Hcl26$27,317
Metoprolol Succinate84$1,738
Amiodarone Hcl115$1,503
Flecainide Acetate35$1,234
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,232
Digoxin64$935
Metoprolol Tartrate91$625
Potassium Chloride33$605
Mexiletine Hcl11$401
Carvedilol47$387
SotalolSotalol Hcl13$349
Furosemide68$262
Amlodipine Besylate33$185
Hydralazine Hcl11$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$172,814242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 266 acute care providers in Oklahoma.

Other acute care in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →